Cancer staging is a standardized process that determines how large a tumor is, whether it has spread, and how far. Doctors use a combination of imaging scans, biopsies, and sometimes surgery to gather the information needed to assign a stage, typically ranging from 0 (very early) to IV (spread to distant parts of the body). That stage then becomes the foundation for every treatment decision that follows.
The TNM System
Most cancers are staged using the TNM system, which evaluates three things independently before combining them into an overall stage number.
- T (Tumor): The size and extent of the primary tumor. T1 is the smallest, and T4 means the tumor has grown extensively into surrounding tissues. TX means the tumor can’t be measured, and T0 means no primary tumor can be found.
- N (Nodes): Whether cancer has reached nearby lymph nodes. N0 means the lymph nodes are clear. N1 through N3 indicate increasing numbers or locations of affected lymph nodes.
- M (Metastasis): Whether cancer has spread to distant parts of the body. M0 means it hasn’t. M1 means it has.
These three values can be further subdivided for precision. A T3 tumor, for instance, might be classified as T3a or T3b depending on exactly how deep it extends. The specific size thresholds and criteria vary by cancer type. A T2 breast cancer and a T2 lung cancer don’t necessarily mean the same thing in terms of tumor size, because different organs have different anatomy and different staging rules.
What Stages 0 Through IV Mean
The TNM values get translated into an overall stage number that gives a quick snapshot of how advanced the cancer is. While the exact TNM combinations that produce each stage differ by cancer type, the general framework is consistent.
Stage 0 refers to abnormal cells that are present but haven’t invaded surrounding tissue. This is sometimes called “carcinoma in situ” and is considered pre-invasive. Stage I typically means a small tumor confined to its organ of origin, with no lymph node involvement and no spread. Stage II generally indicates a larger tumor or limited local spread, but the cancer remains relatively contained.
Stage III usually means the cancer has grown significantly into nearby structures or has reached regional lymph nodes. Stage IV means the cancer has metastasized to distant organs, such as lung cancer spreading to the brain or colon cancer spreading to the liver. Because M1 (distant spread) is present, any cancer with confirmed metastasis is stage IV regardless of the tumor’s size or lymph node status.
Tests Used to Determine Stage
Staging requires a clear picture of where cancer exists in the body, so doctors rely on several types of tests, often in combination.
Imaging scans are typically the first step. CT scans use X-rays from multiple angles to build detailed 3D images and are commonly used to check the chest, abdomen, and pelvis for tumors or enlarged lymph nodes. MRI uses magnetic fields and radio waves to produce high-resolution images, particularly useful for the brain, spinal cord, and soft tissues. PET scans detect areas of unusually high metabolic activity, which can reveal cancer that doesn’t show up well on CT alone. Bone scans look specifically for cancer that may have spread to the skeleton. Ultrasound and standard X-rays round out the toolkit for specific situations.
Biopsies confirm what imaging suggests. A needle biopsy withdraws a small sample of tissue or fluid from a suspicious area. Endoscopic biopsies use a thin, lighted tube inserted through a natural opening (the mouth for a bronchoscopy of the lungs, the anus for a colonoscopy of the colon) to directly view and sample abnormal tissue. Surgical biopsies remove either the entire area of concern (excisional) or just a portion of it (incisional) for examination under a microscope.
The tissue removed during biopsy or surgery provides the most definitive staging information. A pathologist examines the sample to determine how deeply the cancer has invaded, whether it’s present in lymph nodes, and other characteristics like how abnormal the cells look.
Clinical Staging vs. Pathological Staging
Not all staging happens at the same point in time, and the distinction matters. Clinical staging is based on everything known before surgery: physical exams, imaging scans, and biopsy results. It’s the initial estimate that guides early treatment decisions.
Pathological staging happens after surgery, when the removed tumor and lymph nodes can be examined directly under a microscope. This is generally more accurate because it reveals details that imaging can’t detect, like microscopic cancer cells in lymph nodes that appeared normal on a scan. Sometimes the pathological stage is higher or lower than the clinical stage.
A cancer’s original stage stays the same permanently, even if the disease later progresses. If cancer returns or worsens after treatment, doctors perform restaging, using many of the same tests done during the initial workup. Any new stage assigned during restaging is marked with an “r” prefix to distinguish it from the original stage.
How Stage Shapes Treatment
Stage is one of the most important factors in determining what treatment a person receives. Early-stage cancers (stage I or II) are often treated with surgery or radiation, which target the cancer locally and can potentially eliminate it entirely. More advanced cancers (stage III or IV) typically require systemic treatments that travel throughout the body, such as chemotherapy, targeted drug therapy, or immunotherapy, because the cancer has spread beyond what local treatment can reach.
Many treatment plans combine approaches. A stage III cancer might be treated with chemotherapy first to shrink the tumor, followed by surgery, followed by more chemotherapy or radiation. The stage helps doctors decide not just which treatments to use but in what order and how aggressively to pursue them.
Stage also provides a general framework for understanding prognosis. Survival statistics are organized by stage, so knowing your stage helps you and your medical team have more informed conversations about what to expect. That said, stage is one factor among many. Tumor biology, genetic markers, a person’s overall health, and how well the cancer responds to treatment all influence outcomes.
What’s Changing in Cancer Staging
The staging system itself evolves as medical understanding improves. The American Joint Committee on Cancer (AJCC) maintains the standards used across the United States. The organization recently shifted from publishing a single large manual (the 8th Edition is still active for most cancers) to a rolling update system called Version 9, where individual cancer types are updated and released independently. As of January 2026, cancers of the salivary glands and certain throat cancers are being staged under the new Version 9 criteria, with other cancer types expected to follow.
Beyond the staging system itself, newer blood-based tests that analyze circulating tumor DNA are beginning to supplement traditional staging tools. These tests can help identify patients who still have residual cancer cells after treatment, even when imaging scans appear clear. This molecular-level information adds a layer of precision to staging and treatment planning that wasn’t available just a few years ago, particularly for detecting minimal residual disease and guiding decisions about whether additional treatment is needed.